Author:
Martin Karlyn,Moll Stephan
Funder
National Institutes of Health National Heart, Lung, and Blood institute
Reference24 articles.
1. Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome;Becker;Thromb. Haemost.,2010
2. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects;Frost;Br. J. Clin. Pharmacol.,2013
3. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement;Mueck;Thromb. Haemost.,2008
4. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention;Mueck;Clin. Pharmacokinet.,2011
5. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban;Mueck;Clin. Pharmacokinet.,2014
Cited by
44 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献